Allied Market Research has recently unveiled a research study titled „Neurological Biomarkers Market Outlook and Forecast 2021-2031.“ This report delivers a comprehensive analysis of market risks, spotlights opportunities, and provides essential support for strategic and tactical decision-making spanning from 2021 to 2031. The study categorizes the market by pivotal regions propelling its growth and commercialization. Moreover, the report encompasses vital insights into market research and development, growth catalysts, and the evolving investment landscape within Neurological Biomarkers.
Neurological biomarkers market size was valued at $5.4 billion in 2021, and is estimated to reach $18.9 billion by 2031, growing at a CAGR of 13.6% from 2022 to 2031. Ever-increasing rise in the incidence of Alzheimer’s and Parkinson’s is anticipated to contribute toward the robust growth of neurological biomarkers among these two applications. In addition, surge in adoption of neurological biomarkers in drug development and validation has increased over the years to improve the accuracy of clinical trials. Further, rise in transition toward personalized medicine is expected to offer profitable opportunities for the expansion of neurological biomarkers applied across Alzheimer’s and Parkinson’s.
